Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 18

  • 369 clinical trials
  • 123 recruiting
  • 134 conditions
  • 27 countries

Conditions in this area

134 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome29Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Rhinitis allergic16Dry age-related macular degeneration15Diabetic retinal oedema13Dry eye12Retinitis pigmentosa11Age-related macular degeneration10Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Rheumatoid arthritis6+110

Clinical trials in Eye disorders

369 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

369 clinical trials

Conjunctivitis allergic+1

Not recruiting

Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Phleum Pratense Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Conjunctivitis allergic+1

Not recruiting

Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Allergen Extract From Phleum Pratense Pollen, Glutaraldehyde-Modified
  • Sponsor:ROXALL Medizin GmbH

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eye103
  • Sponsor:Eyebiotech Limited

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Effectiveness of VRDN-001 for Patients with Thyroid Eye Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Open angle glaucoma+1

Not recruiting

Study on Goblet Cell Density in Patients with Ocular Hypertension or Primary Open Angle Glaucoma Using Benzalkonium Chloride and Latanoprost Eye Drops

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Latanoprost
  • Sponsor:Region Hovedstaden

Eye disorder+1

Not recruiting

Study on Reducing Eye Prosthesis Discomfort and Discharge Using Retinol Palmitate, Sodium Hyaluronate, and Fluorometholone for Patients with Chronic Symptoms

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Fluorometholone
  • Sponsor:Amsterdam UMC Stichting

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Macular oedema+2

Not recruiting

Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Samsung Bioepis Co. Ltd.

Conjunctivitis allergic+1

Not recruiting

Study of sublingual birch pollen extract (SLI-RX-BET) in different doses for patients with moderate to severe allergic rhinitis caused by birch pollen

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Endocrine ophthalmopathy

Not recruiting

Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003
  • Sponsor:Viridian Therapeutics Inc.

Neovascular age-related macular degeneration

Not recruiting

Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Sjogren's syndrome

Not recruiting

Study on the Effects of Ianalumab in Patients with Sjögren's Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Entecavir
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.